Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:RGLS
- CUSIP: 75915K10
- Web: www.regulusrx.com
Capitalization:- Market Cap: $71.8 million
- Outstanding Shares: 53,182,000
Average Prices:- 50 Day Moving Avg: $1.53
- 200 Day Moving Avg: $1.84
- 52 Week Range: $0.94 - $6.25
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.63
- P/E Growth: -0.03
Sales & Book Value:- Annual Revenue: $722,999.00
- Price / Sales: 99.30
- Book Value: $0.73 per share
- Price / Book: 1.85
Profitability:- EBIDTA: ($77,260,000.00)
- Net Margins: -573.63%
- Return on Equity: -70.38%
- Return on Assets: -53.58%
Debt:- Debt-to-Equity Ratio: 0.27%
- Current Ratio: 7.82%
- Quick Ratio: 7.82%
Misc:- Average Volume: 1.04 million shs.
- Beta: 1.81
- Short Ratio: 3.17
Frequently Asked Questions for Regulus Therapeutics (NASDAQ:RGLS)
What is Regulus Therapeutics' stock symbol?
Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."
How were Regulus Therapeutics' earnings last quarter?
Regulus Therapeutics Inc (NASDAQ:RGLS) announced its quarterly earnings data on Thursday, March, 2nd. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.37) by $0.01. The company earned $0.02 million during the quarter, compared to analysts' expectations of $0.20 million. Regulus Therapeutics had a negative net margin of 573.63% and a negative return on equity of 70.38%. View Regulus Therapeutics' Earnings History.
When will Regulus Therapeutics make its next earnings announcement?
Where is Regulus Therapeutics' stock going? Where will Regulus Therapeutics' stock price be in 2017?
8 brokerages have issued 12-month target prices for Regulus Therapeutics' shares. Their forecasts range from $4.00 to $9.00. On average, they anticipate Regulus Therapeutics' share price to reach $6.17 in the next year. View Analyst Ratings for Regulus Therapeutics.
What are analysts saying about Regulus Therapeutics stock?
Here are some recent quotes from research analysts about Regulus Therapeutics stock:
- 1. According to Zacks Investment Research, "Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. " (3/8/2017)
- 2. Wedbush analysts commented, "RGLS reported Q4/FY16 revenues of $0.02MM/$1.2MM vs. consensus estimates of $0.2MM/$1.4MM and GAAP EPS (loss) of $(0.38)/$(1.55) vs. consensus estimates of $(0.34)/$(1.52). RGLS ended 2016 with cash and cash equivalents of $76.1MM, which we project to provide cash runway into mid:18 aligned with guidance... Following completion of the multiple ascending dose (MAD) study of RG-012 in healthy volunteers in Q2:17, RGLS is planning to initiate a Phase 1/2 renal biopsy study in AS patients that will evaluate RG-012 tissue PK, target engagement, and effects on disease biomarkers. We believe positive results in-line with RGLS' preclinical data could be indicative of future success." (3/6/2017)
- 3. Cowen and Company analysts commented, "Regulus reported Q4 earnings and provided a pipeline update." (3/3/2017)
- 4. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating on RGLS stock, but we are lowering our PT by $4 to $7, as a result of a reduction in our pTS estimate for the RG-101 program from 50% to 25%. We believe that "platform buyers" could still be attracted to the stock, but that investors seeking commercial proof of concept may have been put somewhat at bay given the delay in the FDA lift of the clinical trial hold for RG-101 as a treatment for infection with the HCV." (3/3/2017)
- 5. Needham & Company LLC analysts commented, "RGLS announced late Friday that FDA has extended RG-101 clinical hold and requested additional long-term clinical data from ongoing trials. These data are not expected until 4Q17. We've removed the program from our model considering extensive development risk. Regardless, opportunity for RGLS to capture value in HCV is fading in our view given growing number of effective once-daily oral options. Though we believe microRNA platform has substantial potential, we are downgrading to HOLD due to absence of near-term material clinical milestones. A key value-creating milestone in our view is top-line results from Phase 2 proof-of-concept trial of RG-012 in Alport Syndrome. This trial is expected to begin mid-2017, with results available in 2018. Data from RG-125 Phase 2 trial in NAFLD (collaborator AstraZeneca) are expected 3Q17." (1/30/2017)
Are investors shorting Regulus Therapeutics?
Regulus Therapeutics saw a decline in short interest during the month of April. As of April 28th, there was short interest totalling 3,827,412 shares, a decline of 21.8% from the April 13th total of 4,896,011 shares. Based on an average trading volume of 629,390 shares, the short-interest ratio is presently 6.1 days. Currently, 9.7% of the shares of the stock are short sold.
Who are some of Regulus Therapeutics' key competitors?
Some companies that are related to Regulus Therapeutics include MannKind (MNKD), Fate Therapeutics (FATE), Conatus Pharmaceuticals (CNAT), Uniqure NV (QURE), Pluristem Therapeutics (PSTI), Oncomed Pharmaceuticals (OMED), Evogene Ltd (EVGN), 22nd Century Group (XXII), Sorrento Therapeutics (SRNE), BioDelivery Sciences International (BDSI), CymaBay Therapeutics (CBAY), VIVUS (VVUS), ProQR Therapeutics NV (PRQR), Arrowhead Pharmaceuticals (ARWR), CTI BioPharma Corp (CTIC), Adverum Biotechnologies (ADVM), Cidara Therapeutics (CDTX) and Oramed Pharmaceuticals (ORMP).
Who owns Regulus Therapeutics stock?
Regulus Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Vanguard Group Inc. (2.88%), South Dakota Investment Council (2.51%), Wells Fargo & Company MN (1.48%), Geode Capital Management LLC (0.50%) and Wedbush Securities Inc. (0.34%). Company insiders that own Regulus Therapeutics stock include Alnylam Pharmaceuticals, Inc, Isis Pharmaceuticals Inc, Joseph P Hagan, Stelios Papadopoulos and William H Rastetter. View Institutional Ownership Trends for Regulus Therapeutics.
Who sold Regulus Therapeutics stock? Who is selling Regulus Therapeutics stock?
Regulus Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Goldman Sachs Group Inc., Morgan Stanley, Bank of New York Mellon Corp and California Public Employees Retirement System. View Insider Buying and Selling for Regulus Therapeutics.
Who bought Regulus Therapeutics stock? Who is buying Regulus Therapeutics stock?
Regulus Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., South Dakota Investment Council, Wedbush Securities Inc., Wells Fargo & Company MN, Tudor Investment Corp ET AL, Teachers Advisors LLC, Geode Capital Management LLC and FMR LLC. Company insiders that have bought Regulus Therapeutics stock in the last two years include Joseph P Hagan, Stelios Papadopoulos and William H Rastetter. View Insider Buying and Selling for Regulus Therapeutics.
How do I buy Regulus Therapeutics stock?
Shares of Regulus Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Regulus Therapeutics stock cost?
One share of Regulus Therapeutics stock can currently be purchased for approximately $1.35.
Earnings History for Regulus Therapeutics (NASDAQ:RGLS)Earnings History by Quarter for Regulus Therapeutics (NASDAQ:RGLS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/31/2017 | | | | | | | | |
| 3/2/2017 | Q4 2016 | ($0.37) | ($0.38) | $0.20 million | $0.02 million | View | Listen |  |
| 8/2/2016 | Q216 | ($0.38) | ($0.40) | $0.50 million | $0.48 million | View | Listen | |
| 5/2/2016 | Q1 | ($0.33) | ($0.40) | $2.25 million | $0.49 million | View | Listen | |
| 2/22/2016 | Q415 | ($0.25) | ($0.14) | $5.09 million | $10.90 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.37) | ($0.25) | $3.57 million | $1.87 million | View | N/A | |
| 8/4/2015 | Q215 | ($0.29) | ($0.41) | $2.40 million | $3.80 million | View | N/A | |
| 5/7/2015 | | ($0.26) | ($0.25) | $3.38 million | $4.20 million | View | Listen | |
| 2/18/2015 | | ($0.21) | ($0.47) | $2.24 million | $4.22 million | View | Listen | |
| 11/5/2014 | | ($0.23) | ($0.23) | $2.76 million | $1.08 million | View | Listen | |
| 8/6/2014 | Q214 | ($0.19) | ($0.29) | $3.20 million | $0.74 million | View | N/A | |
| 5/8/2014 | | ($0.14) | ($0.30) | $3.80 million | $1.63 million | View | N/A | |
| 2/27/2014 | | ($0.13) | ($0.11) | | | View | N/A | |
| 8/13/2013 | 2Q13 | ($0.14) | ($0.20) | $3.44 million | $4.80 million | View | N/A | |
| 2/20/2013 | Q412 | ($0.08) | ($0.22) | $3.50 million | $3.24 million | View | N/A | |
| 11/19/2012 | Q312 | | ($15.98) | $3.81 million | $2.80 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Regulus Therapeutics (NASDAQ:RGLS)2017 EPS Consensus Estimate: ($1.05)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.26) | ($0.26) | ($0.26) |
| Q2 2017 | 1 | ($0.26) | ($0.26) | ($0.26) |
| Q3 2017 | 1 | ($0.26) | ($0.26) | ($0.26) |
| Q4 2017 | 1 | ($0.27) | ($0.27) | ($0.27) |
(Data provided by Zacks Investment Research)
Dividend History for Regulus Therapeutics (NASDAQ:RGLS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Regulus Therapeutics (NASDAQ:RGLS)Insider Ownership Percentage: 2.30%
Institutional Ownership Percentage: 50.10%
Insider Trades by Quarter for Regulus Therapeutics (NASDAQ:RGLS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/22/2017 | Stelios Papadopoulos | Director | Buy | 500,000 | $1.22 | $610,000.00 | |
| 3/7/2017 | William H Rastetter | Director | Buy | 250,000 | $1.15 | $287,500.00 | |
| 3/3/2016 | Joseph P Hagan | COO | Buy | 10,000 | $7.19 | $71,900.00 | |
| 2/23/2016 | Alnylam Pharmaceuticals, Inc. | Major Shareholder | Sell | 1,000,000 | $7.18 | $7,180,000.00 | |
| 7/21/2015 | William H Rastetter | Director | Buy | 100,000 | $10.17 | $1,017,000.00 | |
| 7/20/2015 | William H Rastetter | Director | Buy | 38,765 | $10.13 | $392,689.45 | |
| 7/17/2015 | Isis Pharmaceuticals Inc | Major Shareholder | Sell | 343,133 | $10.60 | $3,637,209.80 | |
| 4/21/2015 | Kleanthis G Xanthopoulos | CEO | Sell | 200,000 | $17.15 | $3,430,000.00 | |
| 4/13/2015 | Bruce L A Carter | Director | Sell | 20,000 | $17.66 | $353,200.00 | |
| 3/5/2015 | Kleanthis G Xanthopoulos | CEO | Sell | 89,230 | $20.26 | $1,807,799.80 | |
| 2/2/2015 | Kleanthis G Xanthopoulos | CEO | Sell | 5,700 | $19.61 | $111,777.00 | |
| 1/29/2015 | Kleanthis G Xanthopoulos | CEO | Sell | 145,000 | $18.06 | $2,618,700.00 | |
| 1/28/2015 | Neil W Gibson | Insider | Sell | 80,000 | $18.05 | $1,444,000.00 | |
| 11/28/2014 | Neil W Gibson | Insider | Sell | 2,500 | $19.30 | $48,250.00 | |
| 11/3/2014 | Isis Pharmaceuticals Inc | Major Shareholder | Sell | 1,279,411 | $15.94 | $20,393,811.34 | |
| 10/24/2014 | Alnylam Pharmaceuticals, Inc. | Major Shareholder | Sell | 113,084 | $14.02 | $1,585,437.68 | |
| 10/22/2014 | Neil W Gibson | Insider | Sell | 3,300 | $14.44 | $47,652.00 | |
| 10/10/2014 | Alnylam Pharmaceuticals, Inc. | Major Shareholder | Sell | 2,000 | $6.41 | $12,820.00 | |
| 10/10/2014 | Isis Pharmaceuticals Inc | Director | Sell | 10,050 | $6.56 | $65,928.00 | |
| 10/9/2014 | Isis Pharmaceuticals Inc | Director | Sell | 4,750 | $6.58 | $31,255.00 | |
| 10/8/2014 | Isis Pharmaceuticals Inc | Director | Sell | 3,300 | $6.63 | $21,879.00 | |
| 10/3/2014 | Alnylam Pharmaceuticals, Inc. | Major Shareholder | Sell | 10,300 | $6.74 | $69,422.00 | |
| 10/3/2014 | Isis Pharmaceuticals Inc | Director | Sell | 3,300 | $6.88 | $22,704.00 | |
| 10/2/2014 | Isis Pharmaceuticals Inc | Director | Sell | 3,750 | $6.64 | $24,900.00 | |
| 10/1/2014 | Isis Pharmaceuticals Inc | Director | Sell | 3,250 | $6.71 | $21,807.50 | |
| 9/30/2014 | Kleanthis G Xanthopoulos | CEO | Sell | 2,300 | $7.02 | $16,146.00 | |
| 9/26/2014 | Alnylam Pharmaceuticals, Inc. | Major Shareholder | Sell | 2,500 | $7.04 | $17,600.00 | |
| 9/26/2014 | Isis Pharmaceuticals Inc | Director | Sell | 8,750 | $7.13 | $62,387.50 | |
| 9/25/2014 | Alnylam Pharmaceuticals, Inc. | Major Shareholder | Sell | 2,500 | $7.12 | $17,800.00 | |
| 9/24/2014 | Alnylam Pharmaceuticals, Inc. | Major Shareholder | Sell | 3,750 | $7.19 | $26,962.50 | |
| 9/19/2014 | Alnylam Pharmaceuticals, Inc. | Major Shareholder | Sell | 7,700 | $7.31 | $56,287.00 | |
| 9/19/2014 | Isis Pharmaceuticals Inc | Director | Sell | 4,100 | $7.22 | $29,602.00 | |
| 9/18/2014 | Isis Pharmaceuticals Inc | Director | Sell | 1,500 | $7.40 | $11,100.00 | |
| 9/17/2014 | Isis Pharmaceuticals Inc | Director | Sell | 2,100 | $7.43 | $15,603.00 | |
| 9/12/2014 | Alnylam Pharmaceuticals, Inc. | Major Shareholder | Sell | 8,900 | $7.85 | $69,865.00 | |
| 9/12/2014 | Isis Pharmaceuticals Inc | Director | Sell | 3,500 | $7.96 | $27,860.00 | |
| 9/12/2014 | Neil W Gibson | Insider | Sell | 4,200 | $8.01 | $33,642.00 | |
| 9/11/2014 | Isis Pharmaceuticals Inc | Director | Sell | 3,400 | $7.83 | $26,622.00 | |
| 9/10/2014 | Isis Pharmaceuticals Inc | Director | Sell | 2,000 | $7.70 | $15,400.00 | |
| 9/5/2014 | Isis Pharmaceuticals Inc | Director | Sell | 10,050 | $7.07 | $71,053.50 | |
| 8/29/2014 | Isis Pharmaceuticals Inc | Director | Sell | 1,500 | $6.84 | $10,260.00 | |
| 8/28/2014 | Isis Pharmaceuticals Inc | Director | Sell | 2,000 | $6.96 | $13,920.00 | |
| 8/28/2014 | Kleanthis G Xanthopoulos | CEO | Sell | 3,505 | $7.06 | $24,745.30 | |
| 8/27/2014 | Isis Pharmaceuticals Inc | Director | Sell | 1,500 | $7.21 | $10,815.00 | |
| 8/22/2014 | Alnylam Pharmaceuticals, Inc. | Major Shareholder | Sell | 5,250 | $6.75 | $35,437.50 | |
| 8/21/2014 | Alnylam Pharmaceuticals, Inc. | Major Shareholder | Sell | 2,500 | $6.89 | $17,225.00 | |
| 8/20/2014 | Alnylam Pharmaceuticals, Inc. | Major Shareholder | Sell | 3,000 | $7.14 | $21,420.00 | |
| 8/15/2014 | Alnylam Pharmaceuticals, Inc. | Major Shareholder | Sell | 1,450 | $6.98 | $10,121.00 | |
| 8/14/2014 | Alnylam Pharmaceuticals, Inc. | Major Shareholder | Sell | 1,750 | $7.04 | $12,320.00 | |
| 8/13/2014 | Alnylam Pharmaceuticals, Inc. | Major Shareholder | Sell | 2,250 | $7.02 | $15,795.00 | |
| 8/8/2014 | Isis Pharmaceuticals Inc | Director | Sell | 1,850 | $6.80 | $12,580.00 | |
| 8/7/2014 | Isis Pharmaceuticals Inc | Director | Sell | 2,600 | $6.66 | $17,316.00 | |
| 8/6/2014 | Isis Pharmaceuticals Inc | Director | Sell | 3,150 | $7.08 | $22,302.00 | |
| 8/1/2014 | Isis Pharmaceuticals Inc | Director | Sell | 2,600 | $6.21 | $16,146.00 | |
| 7/31/2014 | Isis Pharmaceuticals Inc | Director | Sell | 1,750 | $6.42 | $11,235.00 | |
| 7/30/2014 | Isis Pharmaceuticals Inc | Director | Sell | 1,000 | $6.60 | $6,600.00 | |
| 7/25/2014 | Isis Pharmaceuticals Inc | Director | Sell | 1,700 | $6.55 | $11,135.00 | |
| 7/24/2014 | Isis Pharmaceuticals Inc | Director | Sell | 1,850 | $6.81 | $12,598.50 | |
| 7/23/2014 | Isis Pharmaceuticals Inc | Director | Sell | 1,700 | $6.88 | $11,696.00 | |
| 7/18/2014 | Isis Pharmaceuticals Inc | Director | Sell | 5,000 | $6.80 | $34,000.00 | |
| 7/17/2014 | Isis Pharmaceuticals Inc | Director | Sell | 5,000 | $6.58 | $32,900.00 | |
| 7/16/2014 | Isis Pharmaceuticals Inc | Director | Sell | 3,500 | $6.59 | $23,065.00 | |
| 7/11/2014 | Isis Pharmaceuticals Inc | Director | Sell | 1,750 | $6.48 | $11,340.00 | |
| 7/10/2014 | Isis Pharmaceuticals Inc | Director | Sell | 4,500 | $6.69 | $30,105.00 | |
| 7/9/2014 | Isis Pharmaceuticals Inc | Director | Sell | 1,800 | $7.08 | $12,744.00 | |
| 2/4/2014 | Sanofi | major shareholder | Buy | 1,303,780 | $7.67 | $9,999,992.60 | |
| 1/21/2014 | Neil Gibson | Insider | Sell | 4,421 | $8.09 | $35,765.89 | |
| 1/17/2014 | Neil Gibson | Insider | Sell | 4,479 | $8.15 | $36,503.85 | |
| 1/16/2014 | Neil Gibson | Insider | Sell | 1,100 | $8.03 | $8,833.00 | |
| 1/2/2014 | Kleanthis Xanthopoulos | CEO | Sell | 3,505 | $7.25 | $25,411.25 | |
| 10/10/2012 | Stanley T Crooke | Director | Buy | 750,000 | $4.00 | $3,000,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Regulus Therapeutics (NASDAQ:RGLS)
Latest Headlines for Regulus Therapeutics (NASDAQ:RGLS)
| Source: |
|
| Date | Headline |
|---|
 | Regulus Therapeutics Inc (RGLS) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 23 at 10:02 AM |
 | EcoR1 Capital, LLC Buys CytomX Therapeutics Inc, Cascadian Therapeutics Inc, Fate Therapeutics ...
www.nasdaq.com - May 20 at 11:44 AM |
| Regulus Therapeutics Inc (RGLS) Sees Large Decrease in Short Interest
www.americanbankingnews.com - May 14 at 8:45 AM |
| FY2017 EPS Estimates for Regulus Therapeutics Inc Decreased by Analyst (RGLS)
www.americanbankingnews.com - May 12 at 12:32 PM |
| Regulus Therapeutics' (RGLS) Hold Rating Reaffirmed at BMO Capital Markets
www.americanbankingnews.com - May 7 at 11:16 AM |
 | Regulus Therapeutics (RGLS) Misses Q1 EPS by 3c, Announces Workforce Reduction; CEO to Resign - StreetInsider.com
www.streetinsider.com - May 5 at 8:16 AM |
 | Edited Transcript of RGLS earnings conference call or presentation 4-May-17 9:00pm GMT
finance.yahoo.com - May 5 at 8:16 AM |
| Regulus reports 1Q loss
finance.yahoo.com - May 5 at 8:16 AM |
| Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring
finance.yahoo.com - May 4 at 7:45 PM |
| Regulus Therapeutics (RGLS) Earning Somewhat Favorable News Coverage, Study Finds
www.americanbankingnews.com - May 4 at 1:42 PM |
| Regulus Therapeutics Inc (RGLS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 4 at 1:04 AM |
| Positive Media Coverage Likely to Impact Regulus Therapeutics (RGLS) Share Price
www.americanbankingnews.com - May 1 at 5:12 PM |
| Somewhat Positive Press Coverage Extremely Likely to Affect Regulus Therapeutics (RGLS) Stock Price
www.americanbankingnews.com - April 28 at 1:17 PM |
| Regulus Therapeutics Inc (RGLS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 28 at 12:02 PM |
| Regulus to Provide First Quarter 2017 Financial Results on May 4, 2017
finance.yahoo.com - April 27 at 7:57 PM |
| Regulus Therapeutics (RGLS) Earns Media Impact Rating of 0.04
www.americanbankingnews.com - April 25 at 7:44 PM |
| Regulus Therapeutics (RGLS) Getting Somewhat Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 16 at 12:15 PM |
| Regulus Therapeutics Inc (RGLS) Short Interest Update
www.americanbankingnews.com - April 15 at 1:18 PM |
| Regulus Therapeutics' (RGLS) Outperform Rating Reiterated at Wedbush
www.americanbankingnews.com - April 4 at 9:44 AM |
| RGLS DEADLINE ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Regulus …
finance.yahoo.com - April 1 at 10:46 AM |
| SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Regulus …
finance.yahoo.com - March 31 at 7:42 PM |
 | DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
us.rd.yahoo.com - March 31 at 7:42 PM |
| RGLS DEADLINE ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Regulus Therapeutics Inc. and a Lead Plaintiff Deadline of April 3, 2017
us.rd.yahoo.com - March 31 at 7:42 PM |
| DEADLINE MONDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm
us.rd.yahoo.com - March 31 at 7:42 PM |
| DEADLINE APRIL 3: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - March 31 at 7:42 PM |
| DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) & Lead Plaintiff Deadline - April 3, 2017
finance.yahoo.com - March 30 at 7:47 PM |
| IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 30 at 7:47 PM |
| SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Regulus Therapeutics, Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline
finance.yahoo.com - March 30 at 7:47 PM |
| DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - March 30 at 7:47 PM |
| Regulus Therapeutics' (RGLS) "Outperform" Rating Reiterated at Wedbush
www.americanbankingnews.com - March 29 at 3:25 PM |
| Regulus to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 28 at 7:20 PM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. -- Lead Plaintiff Deadline of April 3, 2017
finance.yahoo.com - March 28 at 7:20 PM |
| IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Regulus Therapeutics Inc. and Encourages Investors With Losses to Contact the Firm
finance.yahoo.com - March 28 at 7:20 PM |
| SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Regulus Therapeutics Inc. and Encourages Investors With Losses to Contact the Firm
finance.yahoo.com - March 28 at 6:43 AM |
| DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) and Lead Plaintiff Deadline - April 3, 2017
us.rd.yahoo.com - March 24 at 7:21 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. Lead Plaintiff Deadline of April 3, 2017
finance.yahoo.com - March 24 at 7:21 PM |
| Insider Buying: Regulus Therapeutics Inc (RGLS) Director Acquires 500,000 Shares of Stock
www.americanbankingnews.com - March 23 at 7:32 PM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. Lead Plaintiff Deadline of April 3, 2017
finance.yahoo.com - March 22 at 7:28 PM |
| INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 22 at 7:28 PM |
| SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) and Lead Plaintiff Deadline - April 3, 2017
finance.yahoo.com - March 20 at 5:36 PM |
| SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 20 at 5:36 PM |
| RGLS INVESTOR ALERT: The Law Offices of Vincent Wong ... - Yahoo Finance
finance.yahoo.com - March 18 at 8:25 AM |
| SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
us.rd.yahoo.com - March 17 at 7:37 PM |
| SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) and Lead Plaintiff Deadline: April 3, 2017
finance.yahoo.com - March 15 at 7:46 PM |
| INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 15 at 7:46 PM |
| INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 14 at 7:01 PM |
| RGLS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving …
finance.yahoo.com - March 13 at 7:15 PM |
| Regulus Therapeutics Inc (RGLS) Given New $6.00 Price Target at Wedbush
www.americanbankingnews.com - March 12 at 10:02 AM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) and Lead Plaintiff Deadline: April 3, 2017
finance.yahoo.com - March 9 at 7:32 PM |
| IMPORTANT ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 9 at 7:32 PM |
Regulus Therapeutics (RGLS) Chart for Thursday, May, 25, 2017
